Updated Results from Phase 1b/2 Study of BCMA CAR-T Therapy JNJ-4528 Shows Early, Deep and Durable Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CAR-T is a potentially lifesaving option for some CLL patients, but Medicare reimbursement may put it out of reach The CLL Society is part of a working group of other blood cancer nonprofits that are trying to find a long term remedy for how to pay for this therapy. Read more.
Related posts